Abstract
The discovery and development of therapeutic agents for the treatment of human diseases involve a long and complex process (Table I). Through coordinated efforts, researchers with diverse scientific disciplines work together as a team to solve many of the issues illustrated in Table 2. In the past, drug metabolism studies were only conducted to support safety assessment in animals and clinical pharmacology studies in humans in the development process. However, scientists in drug metabolism are now playing an increasingly important role in the design, discovery, and development of new therapeutic agents. The evolution of this approach is in part due to the tremendous progress in cytochrome P450 research and the better understanding of the role of each human cytochrome P450 in drug metabolism and drug-induced toxicity. In fact, much of the knowledge regarding human and animal cytochrome P450s can now be either directly or indirectly applied to many aspects of the drug discovery and development process.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Botsch SB, Gautier JC, Beaune P, Eichelbaum M, Kroemer HK, (1993) Identification and characterization of the cytochrome P450 enzymes involved in N- dealkylation of propafenone:molecular base for interaction potential and variable disposition of active metabolites. Mol. Pharmacol. 43: 120–126
Correia MA, Ortiz de Montellano PR, (1992) Inhibitors of cytochrome P450 and possibilities for their therapeutic application, in Frontiers in Biotransformation, Volume 8, Ruckpaul K, Rein H, (eds). Akademie Verlag Berlin, p 74–144
Gonzalez FJ, Crespi CL, Gelboin HV, (1991) cDNA-expressed human cytochrome P450s: A new age of molecular toxicology and human risk assessment. Mut. Res. 247: 113-127
Guengerich FP, (1989) Characterization of human microsomal cytochrome P450 enzymes. Annu. Rev. Pharmacol. Toxicol. 29: 241–264
Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR (1993) Terfenadine-ketoconazole interaction pharmacokinetic and electrocardiographic consequences. Jama 269: 1513–1518
Humphrey MJ, Smith DA, (1992) Role of metabolism and pharmacokinetic studies in the discovery of new drugs - present and future perspectives. Xenobiotica 22: 743–755
Lu AYH, Miwa GT, Wislocki PG, (1988) Toxicological significance of covalently bound drug residues. Rev. Biochem. Toxicol. 9: 1–27
Marietta MA, (1993) Nitric oxide synthase structure and mechanism. J. Biol. Chem. 268: 12231–12234
Maurice M, Pichard L, Daujat M, Fabre I, Joyeux H, Domergue J, Maurel P (1992) Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. Faseb J. 6: 752–758
Nathan C, (1992) Nitric oxide as a secretory product of mammalian cells. Faseb J. 6: 3051–3064
Spielberg SP, (1984) In vitro assessment of pharmacogenetic susceptibility to toxic drug metabolites in humans. Federation Proc. 43: 2308–2313
Van den Bossche H, (1992) Inhibitors of P450-dependent steroid biosynthesis: From research to medical treatment. J. Steroid Biochem. Molec. Biol. 43: 1003–1021
Walsh JS, Wang R, Bagan E, Wang CC, Wislocki PG, Miwa GT, (1987) Structural alterations that differentially affect the mutagenic and antitrichomonal activities of 5-nitroimidazoles. J. Med. Chem. 30: 150–156
Wang RW, Kari PH, Lu AYH, Thomas PE, Guengerich FP, Vyas KP, (1991) Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch. Biochem. Biophys. 290: 355–361
Woosley RL, Chen Y, Freiman JP, Gillis RA (1993) Mechanism of the cardiotoxic actions of terfenadine. Jama 269: 1532–1536
Wrighton SA, Stevens JC, (1992) The human hepatic cytochromes P450 involved in drug metabolism. Critical Reviews in Toxicol. 22: 1–21
Yun CH, Okerholm RA, Guengerich FP, (1993), Oxidation of the antihistamine drug terfenadine in human liver microsomes-role of cytochrome P450 3A4 in N- dealkylation and C-hydroxylation. Drug Metab. Disp. 21: 403–409
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Lu, A.Y.H. (1995). Therapeutic Agents and Cytochrome P450. In: Arinç, E., Schenkman, J.B., Hodgson, E. (eds) Molecular Aspects of Oxidative Drug Metabolizing Enzymes. NATO ASI Series, vol 90. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-79528-2_24
Download citation
DOI: https://doi.org/10.1007/978-3-642-79528-2_24
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-79530-5
Online ISBN: 978-3-642-79528-2
eBook Packages: Springer Book Archive